nanoliposomal irinotecan + ferumoxytol

**Nanoliposomal irinotecan + ferumoxytol** is an investigational combination therapy comprising **nanoliposomal irinotecan (nal-IRI, MM-398)**—a liposome-encapsulated irinotecan formulation that enables extended release and increased intratumoral conversion to its active metabolite SN-38, providing enhanced topoisomerase I inhibition—and **ferumoxytol**, an intravenous iron oxide nanoparticle (marketed as Feraheme) used primarily for iron deficiency anemia in chronic kidney disease, but also increasingly investigated as an MRI contrast agent, drug delivery vehicle, and for potential immunomodulatory and anticancer effects. The combination is being explored for its possible use in imaging, tumor targeting, and enhanced therapeutic efficacy, particularly in solid tumors such as brain cancer, by leveraging ferumoxytol’s nanoparticle properties for imaging and possible synergistic effects with chemotherapy[1][3][5][7].

Brand names

Feraheme (ferumoxytol)

Other names

nanoliposomal irinotecannal-IRIMM-398MM398MM 398ferumoxytol